InMed Shareholders Approve Directors and Equity Financing Flexibility

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialInMed Pharmaceuticals ( (INM) ) has provided an announcement. On December 17, 2025, InMed Pharmaceuticals held its 2025 Annual General and Special Meeting of Shareholders, where 35.43% of its 2.8 million outstanding common shares were represented in person or by proxy. Shareholders re-elected five directors to serve until the 2026 annual meeting, approved CBIZ CPAs P.C. as the company’s auditor for the coming year, and endorsed the potential issuance of 20% or more of the company’s outstanding common shares as of December 13, 2024 under a Standby Equity Purchase Agreement with YA II PN, Ltd., in line with Nasdaq listing rules, signaling continued shareholder support for the existing board, governance structure and flexible equity financing options. No other matters came to a vote at the meeting, and the company reported the voting results on SEDAR on December 17, 2025. The most recent analyst rating on (INM) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page. Spark’s Take on INM Stock According to Spark, TipRanks’ AI Analyst, INM is a Underperform. InMed Pharmaceuticals’ overall stock score is primarily hindered by its financial performance and valuation concerns. The persistent operational losses and negative cash flows are significant risks. Technical analysis indicates a mildly bearish to neutral trend. The recent $5M private placement is a positive development, but it does not outweigh the broader financial challenges. To see Spark’s full report on INM stock, click here. More about InMed Pharmaceuticals InMed Pharmaceuticals Inc., listed on Nasdaq under the ticker INM and based in Vancouver, is a pharmaceutical company developing a pipeline of proprietary small molecule drug candidates that target the CB1/CB2 receptors, with three main programs in Alzheimer’s disease, ocular disorders and dermatological indications aimed at diseases with high unmet medical needs. Average Trading Volume: 353,224 Technical Sentiment Signal: Sell Current Market Cap: $3.69M Find detailed analytics on INM stock on TipRanks’ Stock Analysis page.